Leadership
SynAct Pharma Appoints Four-Member Nomination Committee Ahead of June 2027 AGM
By News Desk ·
Key takeaways
- SynAct Pharma's Nomination Committee has four members: board chairman Anders Kronborg and three shareholder representatives.
- The committee represents about 14% of SynAct Pharma's total shares and votes as of September 30, 2026.
- Shareholder proposals for the June 10, 2027 AGM must reach the committee by January 31, 2027.
SynAct Pharma AB (publ) has appointed a four-member Nomination Committee ahead of its annual general meeting on June 10, 2027, with board chairman Anders Kronborg joined by three members representing the company's largest shareholders. TradingView reported the appointment on November 18, 2026.
SynAct Pharma's Four-Member Committee
The committee follows the instruction and charter adopted at the AGM held on May 28, 2024, which sets four members: the board chairman and representatives of the three largest shareholders as of the end of September. SynAct Pharma named Niels Ankerstjerne Sloth, appointed by TJ Biotech ApS; Mark Gandrup, appointed by Sanos Group ApS; and Jacob Eriksen, appointed by Hunter Capital.
Together the members represent about 14% of the total number of shares and votes in the company as of September 30, 2026. The committee will prepare proposals to the AGM on the chairman of the meeting, the election of the board chairman and other directors, board remuneration split between the chairman and other members, any remuneration for committee work, and the election and remuneration of the auditor. It will also propose principles for appointing the committee if it considers the current instructions should be updated.
Hunter Capital's involvement follows its August 2026 cash takeover bid for investment company C100, whose board unanimously recommended that shareholders reject the offer of 4.19 SEK per share, Dagens industri reported.
SynAct Pharma's Recent Financing and Patent Moves
According to akta.pro company records, SynAct Pharma completed a directed share issue of 2,883,725 shares at SEK 18.00 in March 2026, raising approximately SEK 51.9 million and extending its cash runway into Q3 2027 to support post-data partnering discussions. The same records show a July 2026 post-IPO debt round of $5.2 million led by Fenja Capital, and a November 2024 capital raise of SEK 65 million to fund resomelagon development for rheumatoid arthritis.
Earlier SynAct Pharma Announcements
In November 2026, SynAct Pharma drew down the second SEK 50 million tranche of its SEK 100 million financing facility with Fenja Capital II A/S and resolved on a directed issue of convertibles with a conversion price of SEK 24.60 per share, a 3.49% dilution, TradingView reported. MarketScreener reported the same month that SynAct Pharma received a USPTO Notice of Allowance for its resomelagon tablet patent. In October 2026, Dagens industri reported that SynAct Pharma signed a strategic agreement with Hipolabor Farmacêutica to jointly develop and commercialize resomelagon for dengue fever treatment in Brazil.
SynAct Pharma's January 2027 Deadline
Shareholders may submit proposals and views to the Nomination Committee by mail to Att: Nomination Committee, c/o SynAct Pharma, Medicon Village, Scheelevägen 2, 223 63 Lund, or by e-mail to [email protected]. Proposals must be submitted no later than January 31, 2027, to be considered. The committee's proposals will be announced in the notice for the 2027 AGM and on SynAct Pharma's website.